Seven randomised trials with prespecified, adjudicated stroke endpoints were pooled, covering 50,617 adults with type 2 diabetes at high cardiovascular risk. Stroke risk was 17% lower on a GLP-1 receptor agonist, while the difference in blood pressure between arms would predict only 4%. In four further trials, in people already living with a neurodegenerative disease, memory and thinking did not improve.
Why it is interesting: Most of the stroke benefit is unexplained by blood pressure, blood glucose or weight loss.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.